QR-Code

Clinical impact of drug-drug interactions on abemaciclib in the real-world experience of AB-ITALY study

Abstract Abemaciclib demonstrated clinical benefit in women affected by HR+/HER2− advanced breast cancer (aBC). Drug-drug interactions (DDIs) can lead to reduced treatment efficacy or increased toxicity. This retro-prospective study aimed to evaluate outcomes, DDIs’ impact, and toxicities of abemaci...

Ausführliche Beschreibung

Gespeichert in:
Hauptverfasser: Simone Scagnoli, Simona Pisegna, Angela Toss, Roberta Caputo, Michelino De Laurentiis, Michela Palleschi, Ugo de Giorgi, Enrico Cortesi, Agnese Fabbri, Alessandra Fabi, Ida Paris, Armando Orlandi, Giuseppe Curigliano, Carmen Criscitiello, Ornella Garrone, Gianluca Tomasello, Giuliana D’Auria, Patrizia Vici, Enrico Ricevuto, Federica Domati, Claudia Piombino, Sara Parola, Roberta Scafetta, Alessio Cirillo, Beatrice Taurelli Salimbeni, Francesca Sofia Di Lisa, Lidia Strigari, Robert Preissner, Maurizio Simmaco, Daniele Santini, Paolo Marchetti, Andrea Botticelli
Format: Artigo
Sprache:Inglês
Veröffentlicht: Nature Portfolio 2024-07-01
Schriftenreihe:npj Breast Cancer
Online-Zugang:https://doi.org/10.1038/s41523-024-00657-z
Tags: Tag hinzufügen
Keine Tags, Fügen Sie das erste Tag hinzu!

Ähnliche Einträge